SIMPLE LAB TEST FOR LOCALIZING GI BLEEDING SITE

胃肠道出血是一个严重的临床问题。隐匿性胃肠道出血在50岁以上的美国人口中高达3-6%，可能是结直肠癌的重要警告信号。因此，隐匿性出血的发现要求进行相当昂贵和不舒服的医学检查，以确定出血是来自下消化道还是上消化道，并排除结直肠癌的存在。然而，大多数GI出血患者的上GI来源并不代表结直肠癌。然而，大多数胃肠道出血患者有上消化道来源，这并不代表结直肠癌。因此，开发一种准确，实用和廉价的测试来区分上消化道和下消化道出血可能会导致医疗保健资源的巨大节省。此外，这样的测试将更好地接受4d的患者与增加的诊断依从性。本研究项目的目的是开发一种简单，实用和廉价的测试，可以将胃肠道出血表征为上或下，并在护理点完成。拟定的商业应用;该产品将是一种即时、非侵入性检测，有助于定位胃肠道出血部位。该测试的最大市场将是对粪便中潜血患者的评估。结直肠筛查项目发现，40岁以上人群中约有4-6%的人检测结果呈阳性，这代表了约600万患者的潜在市场（或每年约7000万美元）。此外，这是一个人口统计学上不断扩大的市场，将有助于确保商业成功。

Gastrointestinal (GI) bleeding is a large and serious clinical problem. Occult GI bleeding is found in as much as 3-6% of the American population over the age of 50 and can be an important warning sign for colorectal cancer. Therefore, the finding of occult bleeding mandates a rather expensive and uncomfortable medical work-up to determine if the bleeding is from a lower or upper GI source and to rule out the presence of a colorectal cancer. However, most patients with GI bleeding with an upper GI source which does not represent a colorectal cancer. However, most patients with GI bleeding have an upper GI source which does not represent a colorectal cancer. Therefore, the development of an accurate, practical and inexpensive test to differentiate between upper and lower GI bleeds could result in a tremendous savings of health care resources. In addition, such a test would be better accept4d by patients with an increased compliance for diagnosis. It is the aim of this research project to develop a simple, practical and inexpensive test that could characterize a GI bleed as upper or lower and be accomplished at the point of care. PROPOSED COMMERCIAL APPLICATIONS; This product will be a point of care, non-invasive test to help in localizing the site of bleeding in the GI tract. The largest market for this test will be in the evaluation of patients with occult blood in their stool. Colorectal screening programs find about 4-6% of the population over the age of 40 have positive tests which represents a potential market of about 6 million patients (or about $70 million per year)> In addition, this is a demographically expanding market that will help assure commercial success.